SequelSEC

NEUROCRINE BIOSCIENCES INC NBIX

Biological Products, (No Diagnostic Substances) · CIK 0000914475 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$3.37B
Fiscal year ended 2026-06-30
Operating income
$794.80M
Fiscal year ended 2026-06-30
Free cash flow
$870.40M
Fiscal year ended 2026-06-30

NEUROCRINE BIOSCIENCES INC (NBIX) reported revenue of $3.37B and net income of $705.50M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from NEUROCRINE BIOSCIENCES INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

NEUROCRINE BIOSCIENCES INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$3.37B
Cost of revenueUnavailable
Gross profitUnavailable
Operating income$794.80M
Net income$705.50M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income$940.20M
Income tax expense$234.70M
Diluted EPSUnavailable
Selling, general & administrative$1.35B
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

NEUROCRINE BIOSCIENCES INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$332.40M
Total assets$5.36B
Current assets$1.64B
Total liabilities$1.67B
Current liabilities$874.50M
Total equity incl. NCI$3.69B
Temporary (mezzanine) equityUnavailable
Inventory$104.20M
Accounts receivable$887.00M
Goodwill$500.60M
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

NEUROCRINE BIOSCIENCES INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$898.10M
Capital expenditures$27.70M
Investing cash flow-$891.20M
Financing cash flow$60.20M
Net change in cash$66.90M
Stock-based compensation$234.50M
Common dividends paidUnavailable
Common share repurchases$66.00M
Depreciation & amortizationUnavailable

Derived

NEUROCRINE BIOSCIENCES INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$870.40M
Gross marginUnavailable
Operating margin23.6%
FCF margin25.8%
SBC / revenue7.0%
Current ratio1.87x
Revenue YoY growth34.4%
Net margin20.9%
R&D / revenueUnavailable
CapEx / revenue0.8%
Long-term debt / equityUnavailable
Effective tax rate25.0%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NBIX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-31View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-11View SEC filing
10-Q · Filed 2025-10-28View SEC filing
10-Q · Filed 2025-07-30View SEC filing
10-Q · Filed 2025-05-05View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.